Yanina Balabanova1, Olga Ignatyeva2, Lena Fiebig3, Vija Riekstina4, Manfred Danilovits5, Kadri Jaama5, Edita Davidaviciene6, Birute Radiulyte6, Christina Marcela Popa7, Vladyslav Nikolayevskyy8, Francis Drobniewski8. 1. Blizard Institute, Queen Mary, University of London, London, UK Department of Infectious Diseases, Imperial College London, London, UK Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany. 2. N.V. Postnikov Samara Region Clinical Tuberculosis Dispensary, Samara, Russia. 3. Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany. 4. Department of Mycobacteriology, State Agency "Infectology Center of Latvia", Clinic for Tuberculosis and Lung Diseases, "Upeslejas" Stopinunovads, Riga, Latvia. 5. United Laboratory, Department of Mycobacteriology, Tartu University Hospital, Tartu, Estonia. 6. National Tuberculosis and Infectious Diseases University Hospital, Vilnius, Lithuania. 7. Marius Nasta Institute of Pneumology, Bucharest, Romania. 8. Blizard Institute, Queen Mary, University of London, London, UK Department of Infectious Diseases, Imperial College London, London, UK.
Abstract
BACKGROUND: The quality of care for patients with TB in Eastern Europe has improved significantly; nevertheless drug resistance rates remain high. We analysed survival in a cohort of patients with multidrug-resistant and extensively drug-resistant (MDR-/XDR-) TB from Latvia, Lithuania, Estonia and Bucharest city. METHODS: Consecutive adult new and retreatment patients with culture-confirmed pulmonary MDR-TB registered for treatment in 2009 (and in 2007 in Latvia) were enrolled; prospective survival information was collected. RESULTS: A total of 737 patients were included into the cohort. Of all MDR-TB cases, 46% were newly diagnosed; 56% of all MDR-TB cases had no additional resistance to fluoroquinolones or injectable agents, 33% had pre-XDR-TB and 11% XDR-TB. Median survival was 5.9 years in patients with MDR-TB and XDR-TB; 1.9 years in patients coinfected with HIV. Older age, male gender, alcohol abuse, retirement, co-morbidities, extrapulmonary involvement and HIV coinfection independently worsened survival. Inclusion of fluoroquinolones and injectable agents improves survival in patients with MDR-TB. Pre-XDR and XDR status did not significantly shorten survival as long as fluoroquinolones and injectable agents were part of the regimen. Moxifloxacin seems to improve survival in ofloxacin-susceptible patients when compared with older generation fluoroquinolones. CONCLUSIONS: The burden of additional resistances in patients with MDR-TB is high likely due to primary transmission of resistant strains. Social and programmatic factors including management of alcohol dependency, expansion of HIV testing and antiretroviral treatment need to be addressed in order to achieve cure and to interrupt transmission. The role of last generation fluoroquinolones and injectable agents in treatment of patients with pre-XDR and XDR-TB needs to be further investigated. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: The quality of care for patients with TB in Eastern Europe has improved significantly; nevertheless drug resistance rates remain high. We analysed survival in a cohort of patients with multidrug-resistant and extensively drug-resistant (MDR-/XDR-) TB from Latvia, Lithuania, Estonia and Bucharest city. METHODS: Consecutive adult new and retreatment patients with culture-confirmed pulmonary MDR-TB registered for treatment in 2009 (and in 2007 in Latvia) were enrolled; prospective survival information was collected. RESULTS: A total of 737 patients were included into the cohort. Of all MDR-TB cases, 46% were newly diagnosed; 56% of all MDR-TB cases had no additional resistance to fluoroquinolones or injectable agents, 33% had pre-XDR-TB and 11% XDR-TB. Median survival was 5.9 years in patients with MDR-TB and XDR-TB; 1.9 years in patients coinfected with HIV. Older age, male gender, alcohol abuse, retirement, co-morbidities, extrapulmonary involvement and HIV coinfection independently worsened survival. Inclusion of fluoroquinolones and injectable agents improves survival in patients with MDR-TB. Pre-XDR and XDR status did not significantly shorten survival as long as fluoroquinolones and injectable agents were part of the regimen. Moxifloxacin seems to improve survival in ofloxacin-susceptible patients when compared with older generation fluoroquinolones. CONCLUSIONS: The burden of additional resistances in patients with MDR-TB is high likely due to primary transmission of resistant strains. Social and programmatic factors including management of alcohol dependency, expansion of HIV testing and antiretroviral treatment need to be addressed in order to achieve cure and to interrupt transmission. The role of last generation fluoroquinolones and injectable agents in treatment of patients with pre-XDR and XDR-TB needs to be further investigated. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: A M W Efsen; A Schultze; R F Miller; A Panteleev; A Skrahin; D N Podlekareva; J M Miro; E Girardi; H Furrer; M H Losso; J Toibaro; J A Caylà; A Mocroft; J D Lundgren; F A Post; O Kirk Journal: J Infect Date: 2017-10-20 Impact factor: 6.072
Authors: Marva Seifert; Sophia B Georghiou; Richard S Garfein; Donald Catanzaro; Timothy C Rodwell Journal: Clin Infect Dis Date: 2017-09-01 Impact factor: 9.079
Authors: Lena Fiebig; Thomas A Kohl; Odette Popovici; Margarita Mühlenfeld; Alexander Indra; Daniela Homorodean; Domnica Chiotan; Elvira Richter; Sabine Rüsch-Gerdes; Beatrix Schmidgruber; Patrick Beckert; Barbara Hauer; Stefan Niemann; Franz Allerberger; Walter Haas Journal: Euro Surveill Date: 2017-01-12
Authors: Christopher G Shield; Benjamin M C Swift; Timothy D McHugh; Rebekah M Dedrick; Graham F Hatfull; Giovanni Satta Journal: Microorganisms Date: 2021-11-16